Roche/Astellas Pharma Inc.’s filing for Tarceva (erlotinib) as a first-line therapy in patients with EGFR-activating mutations could establish the drug more firmly in one of the largest non-small-cell lung cancer disease subtypes.
Astellas announced Nov. 20 that it submitted a supplemental NDA for Tarceva as a first-line therapy in EGFR-mutation positive locally advanced or metastatic NSCLC, based on positive results in the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?